**FDA-approved Indications**

Sildenafil was the first phosphodiesterase-5 (PDE5) inhibitor approved for use, receiving US Food and Drug Administration approval for use in erectile dysfunction on March 27, 1998.

Sildenafil also has FDA approval for the treatment of World Health Organization Group I pulmonary hypertension (also known as pulmonary arterial hypertension (PAH)) in adults to improve exercise tolerance and delay clinical worsening.

**Off-labeled Uses**

Sildenafil is also occasionally used off-label for the treatment of secondary Raynaud phenomenon, female sexual arousal disorder, and as an adjunct in the treatment of altitude-induced hypoxemia.